SCHEMBL3717533

SCHEMBL3717533

c1ccc2c(c1)ccn2N1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.41
CCND1 P24385 4/20 0.41
TSHR P16473 3/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR6 P50406 5/20 0.37
RAD52 P43351 1/20 0.37
ABCB1 P08183 1/20 0.36
NOTUM Q6P988 1/20 0.36
BIRC5 O15392 1/20 0.35
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
PRKD3 O94806 1/20 0.34
PRKCG P05129 1/20 0.34
PRKCB P05771 1/20 0.34
PRKCA P17252 1/20 0.34
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3714611 0.98 CDK4 (0.39) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL8087820 0.98 CDK4 (0.42) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL28745657 0.81 HTR2A (0.44) CDK4CCND1HTR6NOTUMDRD2
SCHEMBL31195323 0.81 HTR2C (0.44) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL1136602 0.81 HTR2C (0.44) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL9703835 0.81 POLB (0.39) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL21047721 0.79 TSHR (0.39) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL21047733 0.79 TSHR (0.36) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL18379331 0.78 CDK4 (0.54) CDK4CCND1TSHRRAB9AL3MBTL1
SCHEMBL27527109 0.75 TSHR (0.46) TSHRRAB9AL3MBTL1HTR6RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647121-A3 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES Novartis AG (CH) 2026-02-18 EP disclosed
EP-4647121-A2 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES Novartis AG (CH) 2025-11-12 EP disclosed
EP-4647121-A2 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES Novartis AG (CH) 2025-11-12 EP disclosed
EP-4393545-B1 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES NOVARTIS AG (CH) 2025-10-08 EP disclosed
US-20250195493-A1 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES NOVARTIS AG (CH) 2025-06-19 US disclosed
US-20250195493-A1 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES NOVARTIS AG (CH) 2025-06-19 US disclosed
US-12285422-B2 Uses of piperidinyl-indole derivatives NOVARTIS AG (CH) 2025-04-29 US disclosed
US-12285422-B2 Uses of piperidinyl-indole derivatives NOVARTIS AG (CH) 2025-04-29 US disclosed
US-12285422-B2 Uses of piperidinyl-indole derivatives NOVARTIS AG (CH) 2025-04-29 US disclosed
EP-4393545-A3 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES Novartis AG (CH) 2024-09-25 EP disclosed
US-20020072611-A1 Antipsychotic heterocycle compounds BRISTOL-MYERS SQUIBB COMPANY 2002-06-13 US disclosed
EP-1087962-A4 PREPARATION OF HETEROARYL COMPOUNDS LILLY CO ELI (US) 2001-10-04 EP disclosed
WO-2001043740-A1 ANTIPSYCHOTIC HETEROCYCLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-06-21 WO disclosed
EP-1087962-A1 PREPARATION OF HETEROARYL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-04-04 EP disclosed
EP-1077213-A2 Inhibition of serotonin reuptake ELI LILLY AND COMPANY (US) 2001-02-21 EP disclosed
US-6046215-A A PIPERIDINYLBENZOTHIOPHENES USEFUL FOR TRATING BRAIN DISORDERS ELI LILLY AND COMPANY (US) 2000-04-04 US disclosed
WO-1999065896-A1 PREPARATION OF HETEROARYL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-12-23 WO disclosed
US-5846982-A Inhibition of serotonin reuptake ELI LILLY AND COMPANY (US) 1998-12-08 US disclosed
WO-1997047302-A1 INHIBITION OF SEROTONIN REUPTAKE ELI LILLY AND COMPANY (US) 1997-12-18 WO disclosed
EP-0812826-A1 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake ELI LILLY AND COMPANY (US) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072611-A1 Antipsychotic heterocycle compounds HTR2C, DRD2, HTR1A CDK4 1558/4885CCND1 547/4885TSHR 97/4885
US-20250195493-A1 NOVEL USES OF PIPERIDINYL-INDOLE DERIVATIVES C5, C3AR1, FCGRT CDK4 1660/4885CCND1 1513/4885TSHR 2798/4885
US-12285422-B2 Uses of piperidinyl-indole derivatives C5, FCGRT, C3AR1 CDK4 2105/4885CCND1 1847/4885TSHR 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.